Litcius/Paper detail

Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial

Michaela Koehm, Tanja Roßmanith, Ann Christina Foldenauer, Eva Herrmann, Jan Brandt‐Jürgens, Gerd R Burmester, Herbert Kellner, Uta Kiltz, David M. Kofler, Jürgen Rech, Sorwe Mojtahed-Poor, Christin Jonetzko, Harald Burkhardt, Frank Behrens, Rieke H.E. Alten, Karolina Benesova, Raoul Bergner, Jürgen Braun, Winfried Demary, Stephanie Finzel, Peter Kästner, Arnd Kleye, Klaus Krüger, Gabriele Lorenz, Regina Max, Denis Poddubnyy, Andrea Rubbert-Roth, Holger Schwenke, Maren Sieburg, Diamant Thaci, Astrid Thiele, Reinhard E. Voll, Ulrich von Hinüber, Jochen Walter, Siegfried Wassenberg

2022The Lancet Rheumatology17 citationsDOI

Topics & Concepts

UstekinumabMedicinePsoriatic arthritisPlaceboMethotrexatePsoriasisAdverse effectInternal medicinePsoriasis Area and Severity IndexConcomitantArthritisRheumatoid arthritisAdalimumabDermatologyPathologyAlternative medicineSpondyloarthritis Studies and TreatmentsRheumatoid Arthritis Research and TherapiesPsoriasis: Treatment and Pathogenesis